Celaid Therapeutics and AGC Ink Research Pact on iPSC-HSPC Expansion and Evaluation
Celaid Therapeutics has partnered with AGC Inc. to advance scalable expansion of iPS cell-derived hematopoietic stem and progenitor cells (iPSC-HSPCs) by combining their respective stem cell technologies.
IPSC Technology | 29/08/2025 | By Mrinmoy Dey | 100
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy